Plus Therapeutics Q1 2023 net loss $4.8M, cash $12.7M; completes ReSPECT-LM Phase 1/Part A

PLUS THERAPEUTICS, INC.

2023-Q1 EPS reported -$0.14

Completed Part A of ReSPECT-LM Phase 1/2a dose escalation trial for rhenium obisbemeda in leptomeningeal metastases.
Q1 cash $12.7M vs $18.1M at Dec 31, 2022; net loss $0.14/share vs $0.19 prior year.
Operating expenses $5.2M, up from $3.9M YoY, driven by $750K milestone payment to NanoTx Corp and clinical enrollment.
Grant revenue $506K from CPRIT; total grant awards of $20.6M from NIH and CPRIT.
Expects to present ReSPECT-GBM and LM data in H2 2023; planning to initiate pediatric trial.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

PLUS THERAPEUTICS, INC. reported first quarter ended March 31, 2023 results: revenue $506,000, net income $4.8 million, EPS $(0.14) per share.

Period: first quarter ended March 31, 2023
Revenue: $506,000
Net income: $4.8 million
EPS: $(0.14) per share
Result: reported results

Exact text from the filing

FIRST QUARTER 2023 FINANCIAL RESULTS ▪ The Company’s cash balance was $12.7 million at March 31, 2023, compared to $18.1 million at December 31, 2022. ▪ The Company recognized $506,000 of grant revenue in the first quarter of 2023, which represents the Cancer Prevention & Research Institute of Texas’ (CPRIT) share of costs incurred in the development of rhenium

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

PLUS THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-013672

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.